This week, Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel ...

Genentech, a member of Roche (RHHBY), announced that a detailed analysis of its Phase III REGENCY trial of Gazyva in people with active lupus ...

Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits ...

4 This announcement follows the assay's CE Mark approval in Ju Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today ... for all outstanding shares of common stock of Poseida Therapeutics, Inc ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We believe that this was related to stock-outs of other products included in the market definition, primarily [indiscernible]. To account for this, the Q3 values were restated to improve accuracy.

Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months.